Inozyme Pharma Inc Market Cap ($258.25 Million)
Market Cap & Net Worth: Inozyme Pharma Inc (INZY)
Inozyme Pharma Inc market cap. Inozyme Pharma Inc (NASDAQ:INZY) has a market capitalization of $258.25 Million ($258.25 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15294 globally and #3635 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Inozyme Pharma Inc's stock price $4.00 by its total outstanding shares 64561800 (64.56 Million). Also see Inozyme Pharma Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Inozyme Pharma Inc Market Cap History (2020–2025)
Inozyme Pharma Inc market cap history from 2020 to 2025. Data shows change from $1.33 Billion to $258.25 Million (-25.85% CAGR). Check INZY live share price for real-time trading data and today's change.
Index Memberships
Inozyme Pharma Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.01% | #406 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1485 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.01% | #211 of 263 |
Weight: Inozyme Pharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Inozyme Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Inozyme Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore INZY shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of INZY by Market Capitalization
Companies near Inozyme Pharma Inc in the global market cap rankings as of November 5, 2026. Also see Inozyme Pharma Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Inozyme Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Inozyme Pharma Inc (2020–2025)
Market capitalization of Inozyme Pharma Inc from 2020 to today. Between 2020 and today, Inozyme Pharma Inc's market cap moved from $1.33 Billion to $ 258.25 Million, with a yearly change of -25.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $258.25 Million | +44.40% |
| 2024 | $178.84 Million | -34.98% |
| 2023 | $275.03 Million | +305.71% |
| 2022 | $67.79 Million | -84.60% |
| 2021 | $440.31 Million | -66.96% |
| 2020 | $1.33 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 1st, 2026 the market cap of Inozyme Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $258.25 Million USD |
| MoneyControl | $258.25 Million USD |
| MarketWatch | $258.25 Million USD |
| marketcap.company | $258.25 Million USD |
| Reuters | $258.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Inozyme Pharma Inc
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney… Read more